On the early morning of December 31, 2014, the good news from PubMed Central has flown through the Editorial Office: Translational Lung Cancer Research (TLCR) has passed the evaluation and is officially indexed by PubMed (Figure 1)! This is one more milestone for TLCR as an acknowledgment of its expansion and dedication to translational research of lung cancer and will tremendously advance its continued exploration in the field.
Figure 1.
Translational Lung Cancer Research (TLCR).
Founded in March 2012, TLCR has been dedicated to providing cutting-edge findings in the rapidly changing field of lung cancer, while providing practical up-to-date information on diagnosis, prevention, and treatment. The goal of the journal is to provide readers with new, well-constructed, informative, and educational information. The Editors-in-Chief are Professor Caicun Zhou from Shanghai Pulmonary Hospital, Professor Yong Song from the Nanjing General Hospital of Nanjing Military Command, and Professor Rafael Rosell from the Pangaea Biotech, Dexeus University Institute, Catalan Institute of Oncology.
Since November 2013, TLCR has been endorsed by Spanish Lung Cancer Group (SLCG) (1). In January 2014, a new office of TLCR was established in General Hospital of Nanjing Military Region, Nanjing, China (Figure 2).
Figure 2.
One scene of the Translational Lung Cancer Research’s (TLCR) editorial office in Nanjing.
Over the past three years, TLCR has published a totality of 16 issues, among which there are focused issues led by the international experts in the field of lung cancer, including Profs. Rafael Rosell, Robert Pirker, Heather Wakelee, Paul Van Schil and others (Table 1). By providing a comprehensive landscape of a specific topic, these focused issues were proved to be well-received with a unique structure and format allowing tremendous progress in our ongoing understanding and sharing of knowledge (Table 2).
Table 1. The focused issues published on Translational Lung Cancer Research (TLCR).
| Volume | Focused Issue | Guest Editor(s) | Affiliation |
|---|---|---|---|
| Vol 2, No 2 | Lung Cancer Issue | Rafael Rosell, Niki Karachaliou | Catalan Institute of Oncology, Head of Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain; Breakthrough Cancer Research Unit, Pangaea Biotech, Barcelona, Spain |
| Vol 2, No 3 | Lung Cancer Issue | Rafael Rosell, Niki Karachaliou | Catalan Institute of Oncology, Head of Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain; Breakthrough Cancer Research Unit, Pangaea Biotech, Barcelona, Spain |
| Vol 2, No 5 | Management of Early Stage Non-small Cell Lung Cancer | Heather Wakelee | Associate Professor of Medicine, Oncology Stanford University, Stanford Cancer Institute, Stanford, CA 94305, USA |
| Vol 3, No 1 | Immunotherapy in Lung Cancer | Yasuhiko Nishioka | Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan |
| Vol 3, No 2 | 10th Congress of Spanish Lung Cancer Group | Rafael Rosell, Bartomeu Massuti, Niki Karachaliou | Director, Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Badalona, Barcelona, Spain & President, Molecular Oncology Research (MORe) Foundation, Barcelona, Spain; Head, Medical Oncology Service, Hospital General de Alicante, Alicante, Spain; Dr Rosell Oncology Institute, Barcelona, Spain |
| Vol 3, No 3 | 4th European Lung Cancer Congress | Paul Van Schil | Department of Thoracic and Vascular Surgery, UZA/Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem (Antwerp), Belgium |
| Vol 3, No 5 | 14th Central European Lung Cancer Congress | Robert Pirker, Caicun Zhou | Division of Oncology, Medical University of Vienna, Vienna, Austria; Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China |
| Vol 3, No 6 | Personalized Therapy in Lung Cancer | Na Zhang, Wen-Zhao Zhong, Yi-Long Wu | Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, China |
Table 2. The most viewed articles published on Translational Lung Cancer Research (TLCR).
| Issue | Title | Authors | Affiliation | Page views |
|---|---|---|---|---|
| Vol 2, No 5 | Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? | Tetsuya Mitsudomi | Department of Thoracic Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan | 16,409 |
| Vol 2, No 2 | KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach | Cristóbal Belda-Iniesta | Medical Oncology Unit-Department of Translational Oncology, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid (Spain) | 5,366 |
| Vol 2, No 1 | Irreversible EGFR-TKIs: dreaming perfection | Federico Cappuzzo | Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy | 4,643 |
| Vol 1, No 1 | Angiogenesis in cancer: anti-VEGF escape mechanisms | Gerald W. Prager | Medical University of Vienna, Comprehensive Cancer Center Vienna, Department of Medicine I, Waehringer Guertel 18-20, AT-1090 Vienna, Austria | 4,525 |
| Vol 2, No 1 | MET inhibition in lung cancer | Jessica Menis | Department of Oncology, A.O.U Santa Maria della Misericordia of Udine, Piazzale Santa Maria della Misericordia, 33100 Udine, Italy | 3,747 |
| Vol 2, No 2 | Activated RET and ROS: two new driver mutations in lung adenocarcinoma | Juergen Wolf | Dep. I of Internal Medicine, University Hospital Cologne, Kerpener Straße 62, D-50937 Köln, Germany | 3,233 |
Particularly, in 2013 Prof. Rafael Rosell and Dr. Niki Karachaliou organized two focused issues on lung cancer in collaboration with the authors from different countries. The two issues cover the new approaches for screening and diagnosis, new target therapy, prognosis and predictive molecular markers and other advanced treatments. They were then delicately translated and made into a Chinese guidebook by Prof. Song Yong and his team to meet the need of a huge population of Chinese physicians, surgeons and healthcare workers.
This October, TLCR published a special issue dedicated to the 14th Central European Lung Cancer Conference (CELCC), guest-edited by Profs. Robert Pirker and Caicun Zhou. The issue was acclaimed for its great content and exquisite layout design on the CELCC congress in Vienna (2) (Figure 3).
Figure 3.
Announcement of the special issue for Central European Lung Cancer Congress (CELCC).
Centering on the research highlights, the 2014 December issue of TLCR also provide profound discussions on the latest clinical research outcomes upon lung cancer recently presented at this year’s ASCO meeting.
To embrace the forthcoming 2015, TLCR is going to publish the following new focused issues and special column (Tables 3,4).
Table 3. Upcoming issues of Translational Lung Cancer Research (TLCR).
| Upcoming Issues | Guest Editor(s) | Affiliation |
|---|---|---|
| Focused Issue | ||
| Molecular Genetics in Lung Cancer | Wendy Cooper | Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050 |
| Imaging and Radiotherapy in Lung Cancer | David Ball | Deputy Director of Radiation Oncology & Cancer Imaging, Chair of Lung Service, Peter MacCallum Cancer Centre, Melbourne, Australia |
| Novel Approaches to In Vivo Imaging of NSCLC | Nhan L. Tran | Division of Cancer and Cell Biology, The Translational Genomics Research Institute, Phoenix, Arizona, USA |
Table 4. New Special Column to be launched in 2015.
| New Special Column | Section Editors | Affiliation |
|---|---|---|
| Controversies in Lung Cancer—Pros and Cons | Suresh Senan | Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands |
| Helmut H. Popper | Research Unit for Molecular Lung & Pleura Pathology, Institute of Pathology, Medical University of Graz, Graz, Austria |
In the end, we would like to express our highest appreciation to the distinguished Editors-in-Chief and editorial board members, respectable authors and readers worldwide for their lasting support and contribution to TLCR. Thanks to your joint efforts, TLCR is finally indexed by PubMed on the last day of 2014 after its inclusion by Medscape. With more confidence, TLCR is working hard toward a robust platform with increased impact for the education, communication and exploration of the international researchers and clinicians.
Acknowledgements
Disclosure: The authors declare no conflict of interest.
References
- 1.TLCR is endorsed by the Spanish Lung Cancer Group (SLCG): new horizons for strong academic collaboration in lung cancer. Available online: http://www.tlcr.org/announcement/view/61 [DOI] [PMC free article] [PubMed]
- 2.Li G.Highlights in the 14th Central European Lung Cancer Conference (CELCC). Transl Lung Cancer Res 2014;3:414-9. [DOI] [PMC free article] [PubMed] [Google Scholar]